

eAppendix Table 1. Frequency and Proportion of Prescription Claims by Year for Oral Anticoagulants in Texas Medicaid (2011-2015), n (%)

Anticoagulants	Year					χ^2	<i>P</i>
	2011	2012	2013	2014	2015		
Dabigatran	992 (2.7)	1573 (3.2)	1926 (3.1)	1935 (3.4)	2418 (4.3)	25,000	<.001
Rivaroxaban	61 (0.2)	1175 (2.4)	5685 (9.1)	7826 (13.6)	7058 (12.6)		
Apixaban	-	-	214 (0.3)	1617 (2.8)	5531 (9.9)		
Edoxaban	-	-	-	-	36 (0.1)		
Warfarin	36,206 (97.2)	46,182 (94.4)	54,761 (87.5)	46,179 (80.2)	41,015 (73.2)		
Total	37,259 (100)	48,930 (100)	62,586 (100)	57,557 (100)	56,058 (100)		

eAppendix Table 2. Frequencies and Proportions of Oral Anticoagulant Prescription Claims by Gender and Age Category

Demographic Variables	Total, n (%)	Dabigatran, n (%)	Rivaroxaban, n (%)	Apixaban, n (%)	Edoxaban, n (%)	Warfarin, n (%)	χ^2	<i>P</i>
Gender								
Female	141,676 (54.0)	4211 (47.6)	12,314 (56.5)	3819 (51.9)	16 (44.4)	121,316 (54.1)	214.1	<.001
Male	120,714 (46.0)	4633 (52.4)	9491 (43.5)	3543 (48.1)	20 (55.6)	103,027 (45.9)		
Age category, years								
18-44	68,581 (26.1)	1278 (14.4)	5775 (26.5)	1428 (19.4)	8 (22.2)	60,092 (26.8)	849.5	<.001
45-63	193,809 (73.9)	7566 (85.6)	16,030 (73.5)	5934 (80.6)	28 (77.8)	164,251 (73.2)		

eAppendix Table 3. Mean Cost Per Prescription (\$) of Oral Anticoagulants by Year in Texas Medicaid (2011-2015)

Drug	Mean Cost Per Prescription (SD)				
	2011	2012	2013	2014	2015
Dabigatran (n = 8844)	258.6 ^a (137.2)	239.9 (75.1)	256.7 ^a (40.5)	290.2 (49.1)	312.4 (60.5)
Rivaroxaban (n = 21,805)	153.2 (79.5)	203.1 (81.2)	257.9 (82.9)	278.2 (94.2)	318.8 (105.1)
Apixaban (n = 7362)	-	-	251.7 (42.8)	285.4 (51.4)	305.4 (77.0)
Edoxaban (n = 36)	-	-	-	-	278.1 (28.4)
Warfarin (n = 224,343)	13.6 (13.8)	9.5 (10.8)	8.5 (11.1)	8.9 (11.6)	10.5 (13.7)
Total (N = 262,390)	20.3 (47.8)	21.6 (54.0)	39.6 (87.0)	62.7 (115.1)	91.6 (142.2)

Analysis of variance showed overall significant model. $F = 120,000$; $df = 18, 262,389$; $P < .001$.

There was a significant interaction between year and drug. $F = 2070.34$; $df = 10, 262,371$; $P < .001$.

Scheffe's post hoc test showed that all group means are significantly different except ^a.

Year 2010 data was excluded due to incomplete data.

eAppendix Table 4. Proportions of Patients Who Switched Oral Anticoagulant Therapy by Index Drug

Index Drug	Switch n (%)	No Switch n (%)	χ^2	<i>P</i>
Dabigatran	46 (17.9)	211 (82.1)	190.9	<.001
Rivaroxaban	212 (24.5)	653 (75.5)		
Apixaban	24 (15.6)	130 (84.4)		
Warfarin	561 (9.2)	5560 (90.8)		